DOCS vs. VTY, RMG, TEM, SPT, GEN, WIX, YOU, CNIC, SRAD, and SLP
Should you be buying Dr. Martens stock or one of its competitors? The main competitors of Dr. Martens include Vistry Group (VTY), Royal Mail (RMG), Templeton Emerging Markets Investment Trust (TEM), Spirent Communications (SPT), Genuit Group (GEN), Wickes Group (WIX), YouGov (YOU), CentralNic Group (CNIC), Stelrad Group (SRAD), and Sylvania Platinum (SLP). These companies are all part of the "computer software" industry.
Dr. Martens vs. Its Competitors
Vistry Group (LON:VTY) and Dr. Martens (LON:DOCS) are both consumer cyclical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.
In the previous week, Dr. Martens had 2 more articles in the media than Vistry Group. MarketBeat recorded 2 mentions for Dr. Martens and 0 mentions for Vistry Group. Dr. Martens' average media sentiment score of 0.62 beat Vistry Group's score of 0.00 indicating that Dr. Martens is being referred to more favorably in the news media.
Vistry Group has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, Dr. Martens has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
Vistry Group pays an annual dividend of GBX 55 per share and has a dividend yield of 8.5%. Dr. Martens pays an annual dividend of GBX 3 per share and has a dividend yield of 4.0%. Vistry Group pays out 73.1% of its earnings in the form of a dividend. Dr. Martens pays out 42.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
Vistry Group has higher revenue and earnings than Dr. Martens. Vistry Group is trading at a lower price-to-earnings ratio than Dr. Martens, indicating that it is currently the more affordable of the two stocks.
76.0% of Vistry Group shares are held by institutional investors. Comparatively, 69.5% of Dr. Martens shares are held by institutional investors. 0.6% of Vistry Group shares are held by company insiders. Comparatively, 4.4% of Dr. Martens shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Dr. Martens has a net margin of 7.89% compared to Vistry Group's net margin of 6.90%. Dr. Martens' return on equity of 18.91% beat Vistry Group's return on equity.
Vistry Group presently has a consensus target price of GBX 613.33, indicating a potential downside of 4.68%. Dr. Martens has a consensus target price of GBX 6,000, indicating a potential upside of 7,894.67%. Given Dr. Martens' stronger consensus rating and higher possible upside, analysts plainly believe Dr. Martens is more favorable than Vistry Group.
Summary
Dr. Martens beats Vistry Group on 11 of the 17 factors compared between the two stocks.
Get Dr. Martens News Delivered to You Automatically
Sign up to receive the latest news and ratings for DOCS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DOCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Martens Competitors List
Related Companies and Tools
This page (LON:DOCS) was last updated on 7/1/2025 by MarketBeat.com Staff
